Hepion Pharmaceuticals Inc (HEPA) Stock Price, Quote & News

Latest News on HEPA

Mar 14, 2025, 8:30 AM EDT - 6 weeks ago

Hepion Pharmaceuticals Announces Reverse Stock Split

Dec 11, 2024, 8:00 AM EST - 4 months ago

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Dec 5, 2024, 8:30 AM EST - 5 months ago

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

Dec 2, 2024, 8:00 AM EST - 5 months ago

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Sep 4, 2024, 9:25 AM EDT - 8 months ago

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Jul 22, 2024, 9:19 AM EDT - 9 months ago

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Apr 19, 2024, 4:30 PM EDT - 1 year ago

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial

Mar 6, 2024, 8:30 AM EST - 1 year ago

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Feb 16, 2024, 8:00 AM EST - 1 year ago

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

Jan 3, 2024, 5:15 PM EST - 1 year ago

Hepion Pharmaceuticals to Present at NASH-TAG 2024

Dec 7, 2023, 8:00 AM EST - 1 year ago

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

Nov 28, 2023, 4:15 PM EST - 1 year ago

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

Nov 10, 2023, 8:50 AM EST - 1 year ago

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat

Oct 25, 2023, 8:30 AM EDT - 1 year ago

Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

Sep 29, 2023, 8:00 AM EDT - 1 year ago

Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules

Sep 21, 2023, 4:05 PM EDT - 1 year ago

Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

Sep 19, 2023, 9:00 AM EDT - 1 year ago

Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer

Sep 14, 2023, 8:45 AM EDT - 1 year ago

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

Sep 6, 2023, 4:30 PM EDT - 1 year ago

Hepion Pharmaceuticals Announces Management Changes

Jun 15, 2023, 4:45 PM EDT - 2 years ago

Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023

Jun 15, 2023, 8:22 AM EDT - 2 years ago

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH' Trial of Rencofilstat

Jun 6, 2023, 7:00 AM EDT - 2 years ago

Theralase(R) Announces Appointment of New Independent Director

May 24, 2023, 4:45 PM EDT - 2 years ago

Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences

May 23, 2023, 5:02 AM EDT - 2 years ago

HEPA stock price surged but beware of this glaring Hepion risk

May 22, 2023, 7:00 AM EDT - 2 years ago

Hepion Pharmaceuticals' Phase 2 ‘ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

May 19, 2023, 4:05 PM EDT - 2 years ago

Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat

May 10, 2023, 11:15 AM EDT - 2 years ago

Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split

Apr 17, 2023, 4:15 PM EDT - 2 years ago

Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023

Mar 30, 2023, 8:45 AM EDT - 2 years ago

Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs

Mar 16, 2023, 4:10 PM EDT - 2 years ago

Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development

Mar 2, 2023, 4:15 PM EST - 2 years ago

Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress

Mar 2, 2023, 9:15 AM EST - 2 years ago

EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion's Patent Portfolio

Feb 9, 2023, 4:15 PM EST - 2 years ago

Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023

Jan 18, 2023, 9:15 AM EST - 2 years ago

Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies

Jan 10, 2023, 4:15 PM EST - 2 years ago

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Jan 5, 2023, 4:15 PM EST - 2 years ago

Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023

Dec 5, 2022, 4:30 PM EST - 2 years ago

Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

Dec 5, 2022, 9:00 AM EST - 2 years ago

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH' Liver Function Trial

Nov 4, 2022, 8:30 AM EDT - 2 years ago

Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock

Oct 26, 2022, 8:00 AM EDT - 2 years ago

Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION' Clinical Trial Results

Oct 20, 2022, 4:30 PM EDT - 2 years ago

Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

Sep 26, 2022, 5:00 PM EDT - 2 years ago

Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

Sep 14, 2022, 8:00 AM EDT - 2 years ago

Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical's Rencofilstat to Treat Alcohol-Related Liver Disease

Jul 22, 2022, 4:15 PM EDT - 3 years ago

Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders

Jun 28, 2022, 8:30 AM EDT - 3 years ago

Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

Jun 24, 2022, 4:15 PM EDT - 3 years ago

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

Jun 20, 2022, 8:00 AM EDT - 3 years ago

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma

Jun 15, 2022, 8:00 AM EDT - 3 years ago

Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022

May 31, 2022, 4:30 PM EDT - 3 years ago

Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting

May 27, 2022, 8:54 AM EDT - 3 years ago

Market Cap	5.05M
Revenue (ttm)	0.00
Net Income (ttm)	-13.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	546,200
Avg Vol	4,748,447
Day's Range	N/A - N/A
Shares Out	10.98M
Stochastic %K	21%
Beta	1.79
Analysts	Strong Buy
Price Target	$30.00